✦ LIBER ✦

1205 ORAL Phase I and Pharmacodynamic Study of High-dose NGR-hTNF in Patients With Refractory Solid Tumours

✍ Scribed by P.A. Zucali; A. Santoro; M. Simonelli; F. De Vincenzo; E. Lorenzi; L. Rimassa; L. Balzarini; V. Quagliuolo; A. Lambiase; C. Bordignon

Book ID: 117661311
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 62 KB
Volume: 47
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(11)70817-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1228 Phase I study of NGR-hTNF, a vascul

1228 Phase I study of NGR-hTNF, a vascular targeting agent (VTA), in combination withcisplatin in refractory patients (pts) with solid tumours

✍ G. Citterio; F.G. De Braud; V. Gregorc; T.M. De Pas; C. Noberasco; S. Boselli; M 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Phase I Study of Three-Times Daily Oral

Phase I Study of Three-Times Daily Oral Etoposide in Patients with Refractory Solid Tumours

✍ Prof. G. Schwartsmann, A. P. F. Caldas, T. Dalla Costa, L. Di Leone, O. Campos J 📂 Article 📅 2000 🏛 Springer International Publishing AG 🌐 English ⚖ 187 KB

Phase Ib study of NGR–hTNF, a selective

Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

✍ Gregorc, V; Santoro, A; Bennicelli, E; Punt, C J A; Citterio, G; Timmer-Bonte, J 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 216 KB

366 POSTER Phase I study of NGR-TNF, a n

366 POSTER Phase I study of NGR-TNF, a novel vascular targeting agent, in patients with refractory solid tumours (EORTC 16041)

✍ C. Van Herpen; W. Fiedler; S. Toma; S. Marreaud; H. Van Laarhoven; P. Lasch; J. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 57 KB

421 POSTER Phase I dose escalation and p

421 POSTER Phase I dose escalation and pharmacokinetic study of oral enzastaurin in Japanese patients with advanced solid tumour

✍ T. Mukohara; S. Nagai; Y. Nambu; K. Yoshizawa; H. Minami 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 63 KB

Phase I clinical, pharmacokinetic and ph

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

✍ Razak, A R A; Hotte, S J; Siu, L L; Chen, E X; Hirte, H W; Powers, J; Walsh, W; 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 308 KB